Abstract
Multi-wall lipid-core nanocapsule (MLNC) functionalized with captopril
and nanoencapsulating furosemide within the core was developed as a
liquid formulation for oral administration. The nanocapsules had mean
particle size below 200 nm, showing unimodal and narrow size
distributions with moderate dispersity (laser diffraction and dynamic
light scattering). Zeta potential was inverted from -14.3 mV
LNC-Fur(0,5) to +18.3 mV after chitosan coating. Transmission
electron microscopy and atomic force microscopy showed spherical
structures corroborating the nanometric diameter of the nanocapsules.
Regarding the systolic pressure, on the first day, the formulations
showed antihypertensive effect and a longer effect than the respective
drug solutions. When both drugs were associated, the anti-hypertensive
effect was prolonged. On the fifth day, a time effect reduction was
observed for all treatments, except for the nanocapsule formulation
containing both drugs Capt(0.5)-Zn(25)-MLNC-Fur(0.45). For diastolic
pressure, only Capt(0.5)-Zn(25)-MLNC-Fur(0.45) presented a significant
difference (p < 0.05) on the first day. On the fifth day, both
Capt(0.5)-MLNC-Fur(0.45) and Capt(0.5)-Zn(25)-MLNC-Fur(0.45) had an
effect lasting up to 24 h. The analysis of early kidney damage marker
showed a potential protection in renal function by
Capt(0.5)-Zn(25)-MLNC-Fur(0.45). In conclusion, the formulation
Capt(0.5)-Zn(25)-MLNC-Fur(0.45) proved to be suitable for hypertension
treatment envisaging an important innovation.
Users
Please
log in to take part in the discussion (add own reviews or comments).